Roivant Sciences(US:ROIV)2025-02-10 17:33Business Updates - Roivant expects MG & CIDP data by March 2025 and TED data in 2H 2025, which could validate the "Deeper is Better" principle[14] - The company anticipates 4 more IMVT-1402 indications by March 2026, adding to the 6 INDs already cleared[14] - A pivotal study could position brepocitinib as the first novel oral DM drug, providing a multi-year lead over competitors[14] - Roivant is advancing LNP litigation with Moderna and Pfizer/BioNTech, with a jury trial in the Moderna case scheduled for September 2025 and a summary judgment phase in 2Q-3Q 2025[14] Financial Highlights - Roivant reported $5.2 billion in cash and marketable securities as of December 31, 2024[25] - The company has approximately $500 million remaining for share repurchases from an original $1.5 billion authorization[25] - Roivant received $259 million from the Dermavant deal, reducing SG&A expenses and eliminating debt, while retaining VTAMA upside with $950 million in sales milestones plus royalties[25] - For the three months ended December 31, 2024, R&D expense was $142 million (adjusted non-GAAP $131 million), and G&A expense was $142 million (adjusted non-GAAP $71 million)[75] - The company's loss from continuing operations, net of tax, was $209 million (adjusted non-GAAP loss of $144 million), excluding $327 million income from discontinued operations, net of tax[75] Pipeline Development - Roivant is initiating a Phase 2 proof-of-concept study of brepocitinib in cutaneous sarcoidosis in 2Q 2025, with topline results expected in 2H 2026[43] - Phase 3 topline data for Batoclimab in Myasthenia Gravis (MG) and Phase 2b data in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are expected in 1Q 2025[20]